Collectively, these findings suggest that CCDC80 might participate in the underlying mechanism of combination treatment of vactosertib with nal-IRI/5-FU/LV in suppressing invasiveness and subsequent pancreatic cancer progression. The gene discussed is CCDC80; the disease is familial pancreatic carcinoma.